Archives
-
Eclipta–Barley Extract and Precocious Puberty in Rats
2026-09-25
A 2025 rat study reports that a combined Eclipta prostrata and Hordeum vulgare extract delayed vaginal opening and reduced ovarian maturation in Danazol- and high-fat-diet-induced models. The findings point to altered hypothalamic GnRH expression as a possible link, while leaving the active constituents, detailed mechanism, and clinical relevance unresolved.
-
Balsalazide: From Colonic Activation to Translation
2026-09-25
Balsalazide links microbial activation in the colon to local 5-aminosalicylic acid activity, offering translational researchers a useful system for studying drug delivery and mucosal inflammation. This article separates established pharmacology from open mechanistic questions and outlines practical choices for model design, assay controls, and interpretation.
-
Calpain Inhibition as a Translational Neurobiology Strategy
2026-09-24
Recent evidence links excessive calpain activity to impaired hippocampal synaptic plasticity after maternal surgery in rats. This article examines what MDL 28170 can—and cannot—establish in translational neuroprotection research, with practical guidance for target attribution, assay design, and model selection.
-
Leupeptin Hemisulfate Salt: Workflow Guide
2026-09-24
Build more interpretable protease, protein-turnover, and autophagy experiments with Leupeptin hemisulfate salt. This workflow guide covers fresh-solution handling, assay controls, and the limits of translating cell-free potency into intact-cell effects.
-
Protease Inhibitor Cocktail for Hair Signaling
2026-09-23
Protect EP4, PI3K/ERK, and lipid-remodeling readouts during extraction without adding EDTA that could chelate divalent cations. This workflow shows where an EDTA-free cocktail helps—and where separate phosphatase protection and assay-specific controls remain essential.
-
VX-765: A Death-Rate-Aware Inflammation Assay
2026-09-23
VX-765 and its active metabolite VRT-043198 provide a selective way to investigate caspase-1-dependent cytokine maturation and pyroptosis. This guide adds a death-rate-aware framework for separating true pathway inhibition from changes in cell growth, survival, or population composition.
-
PMSF in Protein Extraction and Degrader Assays
2026-09-22
Phenylmethanesulfonyl fluoride (PMSF) is more than a routine lysis additive: it can determine whether protein-loss data reflect biology or post-lysis degradation. This guide connects selective serine protease control with rigorous GSPT1 degrader assay interpretation while defining practical limitations.
-
Fumagillin Workflows for Angiogenesis Research
2026-09-22
Fumagillin is a mechanistically targeted methionine aminopeptidase-2 inhibitor for studying endothelial cell proliferation and tumor-associated angiogenesis. This guide combines practical handling, assay design, parasite-screening context, and troubleshooting so researchers can separate validated findings from exploratory applications.
-
MDL 28170: A Selective Calpain Inhibitor Workflow
2026-09-21
MDL 28170 combines nanomolar calpain inhibition with membrane permeability and brain exposure, making it a practical tool for connecting protease activity to neuronal structure and function. This workflow shows how to use it in neuroprotection research, apoptosis assays, and cell-based ischemia-reperfusion injury models while controlling for cathepsin B activity and formulation artifacts.
-
SC 79: A Practical Akt Activator Workflow
2026-09-21
SC 79 is a cytosolic Akt activator for dissecting survival signaling without changing total Akt abundance. This workflow connects neuronal protection, ischemia models, and inflammation-focused pathway studies with practical dosing, washout, assay, and troubleshooting guidance.
-
GSK126: Practical EZH2 Inhibitor Workflows
2026-09-20
GSK126 provides a high-affinity pharmacological route to test how EZH2/PRC2 activity controls H3K27me3, gene silencing, and tumor-cell behavior. This guide translates the compound into reproducible workflows for cancer epigenetics research while clarifying how findings from an antiviral lncRNA study can inform, but not replace, oncology assay design.
-
Protein Integrity in EGFR Resistance
2026-09-19
Hypoxia-driven EGFR inhibitor resistance illustrates why protein preservation is a translational variable. This article connects FGFR1–MAPK biology with practical extraction strategy and explains when an EDTA-free Protease Inhibitor Cocktail can protect phosphorylation-sensitive and interaction-based assays.
-
Brefeldin A: Reliable Assay Design
2026-09-18
Learn how Brefeldin A, SKU B1400, can be integrated into viability, cytotoxicity, trafficking, and apoptosis workflows without confusing transport effects with cell death. This scenario-based guide connects dose selection, solvent handling, endpoint interpretation, and vendor evaluation to practical laboratory decisions.
-
Mycobacterium tuberculosis WecA: Kinetics and Purification
2026-09-18
The reference study establishes a practical route for producing and analyzing Mycobacterium tuberculosis WecA, a difficult 11-transmembrane-domain enzyme involved in mycobacterial cell-wall assembly. By combining tunable expression in Escherichia coli Lemo21(DE3), affinity purification, mass-spectrometric identification, and UMP-based activity detection, the authors created a foundation for kinetic analysis and WecA inhibitor discovery.
-
A1 vs AMD3100 in Colorectal Cancer Models
2026-09-17
Khorramdelazad and colleagues evaluated the fluorinated CXCR4 inhibitor A1 against AMD3100 across molecular, cellular, and mouse colorectal cancer models. A1 showed stronger predicted receptor binding, suppressed CT-26 cell proliferation and migration, reduced immunosuppressive tumor-microenvironment signals, and produced better tumor-control outcomes than AMD3100 in the reported preclinical experiments.